Clinical Trials Logo

Tricuspid Valve Disease clinical trials

View clinical trials related to Tricuspid Valve Disease.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06001489 Recruiting - Clinical trials for Aortic Valve Disease

The Effects of 360-degree Virtual Reality on Pre-procedural Anxiety in Patients Awaiting Elective Cardiac Surgery Involving a Sternotomy

Start date: September 2023
Phase: N/A
Study type: Interventional

Rationale: Patients awaiting cardiac surgery can experience pre-procedural anxiety. This anxiety is associated with increased analgesic needs, increased risk of mortality and prolonged recovery time. Adequate patient education can help diminish pre-procedural anxiety and minimize postoperative complications. Recent studies have demonstrated that Virtual Reality (VR) can function as a useful tool to diminish pre-procedural anxiety in several medical fields. Especially 360 degree VR could familiarize patients with their clinical pathway. Nevertheless, limited to no research on the application of 360 degree VR has been conducted in the context of cardiothoracic surgery yet. Objective: The aim of this study is to explore the effects and possible benefits of 360 degree VR on pre-procedural anxiety in patients awaiting elective cardiac surgery involving a sternotomy, compared to standard forms of patient education. Study design: Single-center, randomized controlled trial Study population: Patients aged 18 or older awaiting elective cardiac surgery involving a sternotomy.

NCT ID: NCT05961150 Recruiting - Clinical trials for Aortic Valve Disease

PROMISE: Percutaneous peRipheral cannulatiOn for Minimally-InvaSive Heart Valve surgEry

Start date: August 1, 2023
Phase:
Study type: Observational

In addition to conventional heart valve surgery (HVS) via full-sternotomy, which is still the most prevalent therapeutic strategy to adress valvular heart disease (VHD), minimally-invasive approaches evolved as safe alternatives, resulting in lower postoperative ventilation times, transfusion rates and shorter in-hospital stay. Femoral artery cannulation is traditionally performed via surgical cutdown to establish cardiopulmonary bypass during minimally-invasive HVS. To avoid groin incision associated infection and lymphocele formation, and further minimize surgical trauma, the use of percutaneous cannulation including novel endovascular closure devices increases as an alternative but remains to be investigated. The Percutaneous peRipheral cannulatiOn for Minimally-InvaSive heart valve surgEry (PROMISE) registry aims to elucidate the safety, feasibility, and effectiveness of newly developed vascular closure devices during minimally-invasive HVS. Acute intra- and perioperative complications will be evaluated according to modified definitions of the Valve Academic Research Consortium (VARC)-3. In addition, based on the initial results, the comparison of percutaneous cannulation with conventional surgical cut-down techniques is planned.

NCT ID: NCT05913908 Recruiting - Clinical trials for Heart Valve Diseases

EFS of the DUO System for Tricuspid Regurgitation (TANDEM II)

TANDEM II
Start date: April 15, 2024
Phase: N/A
Study type: Interventional

The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System).

NCT ID: NCT05797519 Recruiting - Clinical trials for Tricuspid Regurgitation

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation

VISTA
Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of moderate to severe tricuspid regurgitation (TR).

NCT ID: NCT05742906 Recruiting - Clinical trials for Tricuspid Valve Insufficiency

CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study

Start date: August 10, 2022
Phase: N/A
Study type: Interventional

The goal of this pivotal study is to demonstrate the safety and performance of the Cor TRICUSPID ECM (extracellular matrix) Valve (or Cor PEDIATRIC Tricuspid ECM Valve) for the surgical management of tricuspid valve disease and dysfunction in adult and pediatric patients. The main question(s) it aims to answer are: - whether the device may be implanted successfully and safely, and - whether the device effectively treats tricuspid valve disease and dysfunction through 12 months Participants will undergo: - preoperative evaluation - tricuspid valve replacement with the Cor TRICUSPID ECM Valve - postoperative evaluation, including at hospital discharge, 30 days, 6 months, and 12 months, and then annually thereafter through 5 years

NCT ID: NCT04482062 Recruiting - Heart Failure Clinical Trials

TRISCEND II Pivotal Trial

Start date: April 9, 2021
Phase: N/A
Study type: Interventional

Pivotal trial to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system

NCT ID: NCT04231461 Recruiting - Clinical trials for Aortic Valve Stenosis

Quality of Life After Cardiac Surgery

QUACS
Start date: July 19, 2019
Phase:
Study type: Observational

During the last twenty years heart surgery has become safer and the number of patients having heart surgery has increased with more frail patients being offered increasingly complex surgery. Heart operations often improve survival and quality of life (QoL), but that is not true for all patients. Regarding survival, clinicians can measure the risk to life from having a heart operation and the risk to life from not quite precisely, but clinicians have little idea about the impact of heart operations on QoL, which is the outcome that patients care about most. Clinicians are unable to provide patients with robust information on how an operation will affect their QoL. This study will provide this information by analysing the data from patient questionnaires immediately before and after the procedure and monthly thereafter for 12 months.

NCT ID: NCT04097145 Recruiting - Clinical trials for Tricuspid Regurgitation

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

CLASP II TR
Start date: December 11, 2019
Phase: N/A
Study type: Interventional

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team

NCT ID: NCT03859102 Recruiting - Clinical trials for Coronary Artery Disease

Enhanced Recovery After Cardiac Surgery

ERAS
Start date: December 17, 2018
Phase: N/A
Study type: Interventional

Enhanced Recovery Protocols (ERPs or bundles) have been established in many surgical specialties (such as colon cancer and orthopaedic joint surgeries) for several years in hospitals worldwide. The principles of Enhanced Recovery Protocols are those of early mobilization and restoration of normal function as soon as possible after surgery. These principles are achieved by use of alternate pain control regimens and removing invasive lines and drains as soon as possible. The benefits of ERPs are improved patient experience, earlier return to normal function and reduced length of stay. Enhanced recovery protocols for cardiac surgery have been published by the Enhanced Recovery After Cardiac Surgery Society. The current study will investigate whether it is possible to utilise ERP bundles in the population of cardiac surgery patients at James Cook Hospital, with a view to rolling out a full ERP service. Secondary study outcomes will be patient-centred, including; pain scores, nausea and vomiting rates and time taken to return to normal function.

NCT ID: NCT03546231 Recruiting - Clinical trials for Tricuspid Valve Disease

Characteristics and Prognosis of Moderate or Severe Tricuspid Regurgitation

EPIT
Start date: March 2, 2018
Phase:
Study type: Observational

The tricuspid valve : its evaluation is relatively difficult in echocardiography and the management of tricuspid valve diseases remains poorly codified.